Tech Company Inital Public Offerings
Histogenics IPO
Headquartered in Waltham, Histogenics is now a public company.
Transaction Overview
Company Name
Announced On
12/3/2014
Transaction Type
IPO
Amount
$64,900,000
Proceeds Purpose
Proceeds purposes are on file with company statements at the SEC.
Company Information
Company Status
Publicly-held
Industry
Medical Devices & Instruments
Mailing Address
830 Winter St. 3rd Floor
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Website
Email Address
Overview
Histogenics (NASDAQ: HSGX) is a tissue regeneration company developing breakthrough treatments for long-lasting joint repair.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Adam Gridley
Chief Financial Officer
Jon Lieber
Chief Operating Officer
Stephen Kennedy
VP - Bus. Development
Donald Haut
VP - Engineering
Caroline Dugopolski
VP - Finance
Harris Shuman
VP - Operations
Peter Hamilton
Browse more venture capital transactions:
Prev: 12/3/2014: Audentes Therapeutics venture capital transaction
Next: 12/3/2014: Strap venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs